Simcere Zaiming Doses First US Patient in SIM0500 Phase 1 Trial
Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced the first US patient has started treatment in the ongoing Phase 1...
Tag : multiple myeloma
Exicure Plans New Clinical Trial for Acute Myeloid Leukemia
Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. (“Exicure”) is planning for a...